{"title":"刚地弓形虫C2结构域蛋白缺失突变体作为抗小鼠弓形虫病疫苗的前景","authors":"Yifan Luo, Mingfeng He, Shengqiang Yang, Jiahui Qian, Zhengming He, Jiayin Xu, Liyu Guo, Siyu Xiao, Rui Fang","doi":"10.1111/1751-7915.70143","DOIUrl":null,"url":null,"abstract":"<p><i>Toxoplasma gondii</i> (<i>T. gondii</i>), a parasitic protozoan capable of infecting nearly all warm-blooded animals, causes significant economic losses in livestock and poses a significant threat to both animal and public health. Despite its impact, no ideal vaccine is currently available to prevent toxoplasmosis. Vesicular transport plays a crucial role in the life cycle of <i>T. gondii</i>, and proteins involved in this process – such as those containing C2 domains – may serve as novel targets for the development of live attenuated vaccines. In this study, we evaluated the feasibility of a C2 domain-containing protein (TGME49_203240) as a live attenuated vaccine candidate. Our findings suggest that TGME49_203240 may be involved in vesicular transport and that it is essential for <i>T. gondii</i> growth. Deletion of TGME49_203240 reduced parasite virulence and impaired tissue cyst formation in mice. Moreover, mice vaccinated with ME49<i>Δ203240</i> were protected against the lethal challenge of the tachyzoites of <i>T. gondii</i> I, II, III strains and cysts of II strain. In addition, the ME49<i>Δ203240</i> strain elicited robust immune responses, including the production of high levels of specific IgG antibodies and key cytokines (IFN-γ, TNF-α and IL-12). These findings highlight TGME49_203240 as a promising target for the development of a live attenuated vaccine against <i>T. gondii</i>.</p>","PeriodicalId":209,"journal":{"name":"Microbial Biotechnology","volume":"18 5","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1751-7915.70143","citationCount":"0","resultStr":"{\"title\":\"Toxoplasma gondii C2 Domain Protein Deletion Mutant as a Promising Vaccine Against Toxoplasmosis in Mice\",\"authors\":\"Yifan Luo, Mingfeng He, Shengqiang Yang, Jiahui Qian, Zhengming He, Jiayin Xu, Liyu Guo, Siyu Xiao, Rui Fang\",\"doi\":\"10.1111/1751-7915.70143\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><i>Toxoplasma gondii</i> (<i>T. gondii</i>), a parasitic protozoan capable of infecting nearly all warm-blooded animals, causes significant economic losses in livestock and poses a significant threat to both animal and public health. Despite its impact, no ideal vaccine is currently available to prevent toxoplasmosis. Vesicular transport plays a crucial role in the life cycle of <i>T. gondii</i>, and proteins involved in this process – such as those containing C2 domains – may serve as novel targets for the development of live attenuated vaccines. In this study, we evaluated the feasibility of a C2 domain-containing protein (TGME49_203240) as a live attenuated vaccine candidate. Our findings suggest that TGME49_203240 may be involved in vesicular transport and that it is essential for <i>T. gondii</i> growth. Deletion of TGME49_203240 reduced parasite virulence and impaired tissue cyst formation in mice. Moreover, mice vaccinated with ME49<i>Δ203240</i> were protected against the lethal challenge of the tachyzoites of <i>T. gondii</i> I, II, III strains and cysts of II strain. In addition, the ME49<i>Δ203240</i> strain elicited robust immune responses, including the production of high levels of specific IgG antibodies and key cytokines (IFN-γ, TNF-α and IL-12). These findings highlight TGME49_203240 as a promising target for the development of a live attenuated vaccine against <i>T. gondii</i>.</p>\",\"PeriodicalId\":209,\"journal\":{\"name\":\"Microbial Biotechnology\",\"volume\":\"18 5\",\"pages\":\"\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1751-7915.70143\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Microbial Biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/1751-7915.70143\",\"RegionNum\":2,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Microbial Biotechnology","FirstCategoryId":"5","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1751-7915.70143","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Toxoplasma gondii C2 Domain Protein Deletion Mutant as a Promising Vaccine Against Toxoplasmosis in Mice
Toxoplasma gondii (T. gondii), a parasitic protozoan capable of infecting nearly all warm-blooded animals, causes significant economic losses in livestock and poses a significant threat to both animal and public health. Despite its impact, no ideal vaccine is currently available to prevent toxoplasmosis. Vesicular transport plays a crucial role in the life cycle of T. gondii, and proteins involved in this process – such as those containing C2 domains – may serve as novel targets for the development of live attenuated vaccines. In this study, we evaluated the feasibility of a C2 domain-containing protein (TGME49_203240) as a live attenuated vaccine candidate. Our findings suggest that TGME49_203240 may be involved in vesicular transport and that it is essential for T. gondii growth. Deletion of TGME49_203240 reduced parasite virulence and impaired tissue cyst formation in mice. Moreover, mice vaccinated with ME49Δ203240 were protected against the lethal challenge of the tachyzoites of T. gondii I, II, III strains and cysts of II strain. In addition, the ME49Δ203240 strain elicited robust immune responses, including the production of high levels of specific IgG antibodies and key cytokines (IFN-γ, TNF-α and IL-12). These findings highlight TGME49_203240 as a promising target for the development of a live attenuated vaccine against T. gondii.
期刊介绍:
Microbial Biotechnology publishes papers of original research reporting significant advances in any aspect of microbial applications, including, but not limited to biotechnologies related to: Green chemistry; Primary metabolites; Food, beverages and supplements; Secondary metabolites and natural products; Pharmaceuticals; Diagnostics; Agriculture; Bioenergy; Biomining, including oil recovery and processing; Bioremediation; Biopolymers, biomaterials; Bionanotechnology; Biosurfactants and bioemulsifiers; Compatible solutes and bioprotectants; Biosensors, monitoring systems, quantitative microbial risk assessment; Technology development; Protein engineering; Functional genomics; Metabolic engineering; Metabolic design; Systems analysis, modelling; Process engineering; Biologically-based analytical methods; Microbially-based strategies in public health; Microbially-based strategies to influence global processes